{"product_id":"sldb-vrio-analysis","title":"Solid Biosciences Inc. (SLDB): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eDiscover the true engine behind Solid Biosciences Inc. (SLDB)'s competitive edge! This VRIO analysis cuts straight to the core, revealing precisely which of its resources are truly Valuable, Rare, Inimitable, and Organized for success. Uncover the secrets to their sustainable advantage - or the critical gaps they must address - by diving into the full breakdown below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSolid Biosciences Inc. (SLDB) - VRIO Analysis: 1. SGT-003 Clinical Data and Safety Profile (Duchenne)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at a next-generation gene therapy candidate, SGT-003, and wondering if the early clinical signals translate into a durable edge. Honestly, the data coming out of the INSPIRE DUCHENNE trial as of late 2025 is compelling, especially given the safety profile achieved so far. The key takeaway is that Solid Biosciences has generated a unique dataset supporting their low-dose, steroid-only approach, which is a significant near-term advantage in a crowded field.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Proof-of-Concept and Safety Tolerability\u003c\/h3\u003e\n\u003cp\u003eThe clinical data for SGT-003 demonstrates clear proof-of-concept for their next-gen approach in Duchenne. As of the October 31, 2025, cutoff, 23 pediatric participants have been dosed in the Phase 1\/2 INSPIRE DUCHENNE trial. The therapy has been generally well tolerated using a steroid-only prophylactic immunomodulation regimen, which is a big deal compared to more intensive protocols used by others. Specifically, there were no cases of drug-induced liver injury observed in those 23 patients. Day 90 biopsy data from 10 treated participants showed a mean muscle microdystrophin expression of 58%. Also, strong statistical correlations were observed between this expression and the restoration of the dystrophin-associated protein complex (DAPC), with markers like beta-sarcoglycan showing an $r$ value of 0.95.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on efficacy signals:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMean microdystrophin expression (Day 90): \u003cstrong\u003e58%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eParticipants dosed (as of Oct 31, 2025): \u003cstrong\u003e23\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCK reduction correlation: $r = \\mathbf{-0.78}$\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhat this estimate hides is the long-term durability, but the early signals are defintely positive.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Differentiated Delivery and Regimen\u003c\/h3\u003e\n\u003cp\u003eThe rarity here isn't just achieving expression; it’s the combination of how they achieved it. The use of their proprietary AAV-SLB101 capsid is designed for enhanced skeletal muscle and cardiac tropism while reducing liver targeting. This proprietary vector, combined with the fact that they are seeing these results on a steroid-only regimen, is quite rare in the Duchenne gene therapy space right now. Competitors often require more complex or intensive immunosuppression protocols, so this cleaner safety signal is a rare find.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Proprietary Data Package and Vector\u003c\/h3\u003e\n\u003cp\u003eImitability is high because the specific clinical data package - the combination of microdystrophin expression, DAPC restoration correlations, and safety profile - is unique to their trial execution and the AAV-SLB101 vector. While competitors can try to design similar vectors, replicating the exact in-human data set Solid Biosciences has built over the last year takes time and capital. Furthermore, Solid has already executed over 30 agreements or licenses for the AAV-SLB101 capsid, showing others recognize its unique potential.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Pipeline Focus and Regulatory Path\u003c\/h3\u003e\n\u003cp\u003eThe company appears highly organized around advancing this lead asset. They are actively recruiting for the Phase 3 ex-U.S. trial, IMPACT DUCHENNE, and plan to meet with the U.S. Food and Drug Administration (FDA) in the first half of 2026 to discuss a potential registrational pathway for SGT-003. Plus, they are advancing two other pipeline assets, SGT-212 (Friedreich's Ataxia) and SGT-501 (CPVT), showing a broader organizational commitment to their platform technologies. They ended Q2 2025 with $268.1 million in cash, projecting a runway through H1 2027, which supports this focused execution.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Temporary Lead\u003c\/h3\u003e\n\u003cp\u003eThe current competitive advantage is best characterized as \u003cstrong\u003eTemporary\u003c\/strong\u003e. The robust, clean data set from the INSPIRE DUCHENNE trial provides a strong first-mover advantage for SGT-003 in this specific therapeutic window and dosing strategy. However, the nature of biotech means competitors will aggressively work to match or surpass these expression levels and safety profiles. The advantage is tied directly to being the first to show these specific results with this specific vector.\u003c\/p\u003e\n\n\u003cp\u003eHere is a summary of the VRIO assessment for the SGT-003 clinical data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eKey Supporting Data (2025 Fiscal Year)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eMean microdystrophin expression of \u003cstrong\u003e58%\u003c\/strong\u003e in 10 patients at Day 90\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eSteroid-only immunomodulation regimen; proprietary AAV-SLB101 capsid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (I)\u003c\/td\u003e\n\u003ctd\u003eDifficult\/Costly\u003c\/td\u003e\n\u003ctd\u003eProprietary clinical data package; over 30 AAV-SLB101 licensing agreements executed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eOn track for H1 2026 FDA pathway discussion; $268.1 million cash runway into H1 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eStrong near-term lead based on current safety\/efficacy data profile\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFinance: Finalize the sensitivity analysis on the H1 2027 cash runway based on a delayed Phase 3 initiation by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSolid Biosciences Inc. (SLDB) - VRIO Analysis: 2. AAV-SLB101 Proprietary Capsid Technology\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This is the delivery workhorse; it enables lower dosing and has shown reduced liver targeting, which is a major safety advantage in gene therapy.\u003c\/p\u003e\n\u003cp\u003eThe AAV-SLB101 capsid was rationally designed to target integrin receptors, showing enhanced cardiac and skeletal muscle transduction with decreased liver targeting in nonclinical studies. In preclinical studies, it demonstrated increased transduction speed, enhanced skeletal and cardiac muscle tropism, decreased liver biodistribution, and improved efficiency when compared to first-generation capsids. The investigational gene therapy SGT-003, which utilizes AAV-SLB101, is being evaluated in the INSPIRE DUCHENNE trial at a dose of \u003cstrong\u003e1E14vg\/kg\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eParticipants Dosed (INSPIRE DUCHENNE)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e23\u003c\/strong\u003e pediatric participants\u003c\/td\u003e\n\u003ctd\u003eAs of October 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety Status\u003c\/td\u003e\n\u003ctd\u003eGenerally well tolerated\u003c\/td\u003e\n\u003ctd\u003eAs of October 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSGT-003 Full Capsid Ratio (GMP Scale)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e80%\u003c\/strong\u003e full capsids\u003c\/td\u003e\n\u003ctd\u003eCurrent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; while AAV capsids are common, a rationally designed, proprietary one with proven clinical utility and external licensing interest is less common.\u003c\/p\u003e\n\u003cp\u003eThe capsid is proprietary and has demonstrated positive early clinical safety data, supporting its rarity as a validated next-generation vector.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate to High; it requires significant R\u0026amp;D investment and know-how to design and validate in human trials.\u003c\/p\u003e\n\u003cp\u003eThe development and validation of AAV-SLB101 are supported by substantial R\u0026amp;D investment, as evidenced by company financials.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and development expenses for the full year ended December 31, 2024, were \u003cstrong\u003e$96.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the three months ended March 31, 2024, were \u003cstrong\u003e$18.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the company is actively exploiting this by executing over 25 licensing agreements with academic labs and corporations.\u003c\/p\u003e\n\u003cp\u003eSolid Biosciences is actively monetizing and expanding the reach of the AAV-SLB101 platform through broad out-licensing agreements.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSolid has established \u003cstrong\u003emore than 30 agreements and licenses\u003c\/strong\u003e executed for the use of AAV-SLB101.\u003c\/li\u003e\n\u003cli\u003eThese agreements include non-exclusive worldwide licenses with entities such as Kinea Bio and Andelyn Biosciences.\u003c\/li\u003e\n\u003cli\u003eAgreements provide for revenue streams including upfront payments, development and sales milestones, and tiered royalties on net sales.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, if they continue to build out the library and secure broad IP protection around its use.\u003c\/p\u003e\n\u003cp\u003eThe advantage is sustained by the demonstrated clinical validation in the INSPIRE DUCHENNE trial and the ongoing expansion of the licensing ecosystem.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe technology has been validated through its use in SGT-003, which has a cleared Investigational New Drug (IND) application.\u003c\/li\u003e\n\u003cli\u003eThe company held approximately \u003cstrong\u003e$206.1 million\u003c\/strong\u003e in cash, cash equivalents, and available-for-sale securities as of March 31, 2024, providing funding into 2026 to support pipeline and business development activities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSolid Biosciences Inc. (SLDB) - VRIO Analysis: 3. Diversified Three-Asset Clinical Pipeline (Duchenne, FA, CPVT)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Reduces single-asset risk by targeting three distinct, high-unmet-need rare diseases (Duchenne, Friedreich's Ataxia, CPVT).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; having three distinct programs in or near Phase 1b trials simultaneously is a significant achievement for a company of this size.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; competitors can pursue other rare diseases, but replicating this specific portfolio progression timeline is difficult.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the strategic expansion shows a clear organizational focus on becoming a multi-program leader in genetic medicine.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as pipeline breadth offers multiple shots on goal for value creation.\u003c\/p\u003e\n\u003cp\u003ePipeline progression data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eLatest Stage\/Event (as of late 2025)\u003c\/th\u003e\n\u003cth\u003eDosing\/Enrollment Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSGT-003\u003c\/td\u003e\n\u003ctd\u003eDuchenne\u003c\/td\u003e\n\u003ctd\u003eFDA meeting planned for \u003cstrong\u003eH1 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e23 participants\u003c\/strong\u003e dosed as of October 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSGT-212\u003c\/td\u003e\n\u003ctd\u003eFriedreich's Ataxia (FA)\u003c\/td\u003e\n\u003ctd\u003ePhase 1b FALCON trial site activation in \u003cstrong\u003eQ4 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eScreening participants\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSGT-501\u003c\/td\u003e\n\u003ctd\u003eCPVT\u003c\/td\u003e\n\u003ctd\u003ePhase 1b ARTEMIS trial site activation expected in \u003cstrong\u003eQ4 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A (First-in-human expected)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinancial and liquidity metrics supporting organizational capacity:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eReporting Period\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, etc.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$236.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnd of \u003cstrong\u003eQ3 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eH1 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eBased on \u003cstrong\u003eQ2 2025\u003c\/strong\u003e figures\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.69\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest reporting period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6.74\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest reporting period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$32.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ2 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSpecific program details supporting Value and Rarity:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSGT-003 initial data showed robust microdystrophin expression and reduced liver targeting with proprietary capsid AAV-SLB101.\u003c\/li\u003e\n\u003cli\u003eSGT-212 is the first gene therapy candidate for FA to utilize a dual route of administration.\u003c\/li\u003e\n\u003cli\u003eSGT-501 received FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations.\u003c\/li\u003e\n\u003cli\u003eThere are currently \u003cstrong\u003eno approved treatments\u003c\/strong\u003e that address the underlying mechanisms of CPVT.\u003c\/li\u003e\n\u003cli\u003eSolid has executed over \u003cstrong\u003e30 agreements\u003c\/strong\u003e including licenses with corporations, institutions, and academic labs for the use of AAV-SLB101 as of Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSolid Biosciences Inc. (SLDB) - VRIO Analysis: 4. Financial Runway and Cash Position\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides the necessary operational stability to execute on multiple clinical trials without immediate dilution pressure.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; a cash position of \u003cstrong\u003e$236.1 million\u003c\/strong\u003e as of Q3 2025, funding operations into \u003cstrong\u003eH1 2027\u003c\/strong\u003e, is solid for a clinical-stage biotech.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a function of past financing, not an inherent operational capability, though prudent management is key.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; management has successfully managed burn rate to secure a long runway, which is crucial for definitely advancing trials.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as cash reserves deplete over time, but it buys critical time now.\u003c\/p\u003e\n\u003cp\u003eThe current financial standing is directly attributable to recent capital deployment and financing activities, as evidenced by the Q3 2025 financial snapshot:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eAmount (USD Millions)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$236.1\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$45.8\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development (R\u0026amp;D) Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$38.9\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral and Administrative (G\u0026amp;A) Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.2\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$48.1\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Runway\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eH1 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe cash runway into \u003cstrong\u003eH1 2027\u003c\/strong\u003e is supported by the balance sheet as of September 30, 2025, which includes gross proceeds from the \u003cstrong\u003e$200.0 million\u003c\/strong\u003e underwritten offering completed in February 2025. The increase in R\u0026amp;D spending to \u003cstrong\u003e$38.9 million\u003c\/strong\u003e in Q3 2025 reflects the active advancement of pipeline programs.\u003c\/p\u003e\n\u003cp\u003eKey operational milestones enabled by this financial position include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDosing of \u003cstrong\u003e23\u003c\/strong\u003e participants in the Phase 1\/2 INSPIRE DUCHENNE clinical trial as of Q3 2025, with plans to dose \u003cstrong\u003e30\u003c\/strong\u003e by early 2026.\u003c\/li\u003e\n\u003cli\u003eContinued progression of SGT-212 for Friedreich's ataxia and SGT-501 for CPVT.\u003c\/li\u003e\n\u003cli\u003eThe cash position of \u003cstrong\u003e$236.14 million\u003c\/strong\u003e is offset by \u003cstrong\u003e$21.94 million\u003c\/strong\u003e in total debt, resulting in a net cash position of \u003cstrong\u003e$214.21 million\u003c\/strong\u003e, or \u003cstrong\u003e$2.75\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSolid Biosciences Inc. (SLDB) - VRIO Analysis: 5. SGT-212 Dual-Route Delivery Method (FA)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSGT-212 addresses both the neurologic via direct IDN infusion and systemic\/cardiac manifestations of Friedreich's Ataxia in one therapy, a novel approach. The therapy is designed to deliver full-length human frataxin (Fxn) via dual routes: intradentate nucleus (IDN) infusion, using an MRI-guided device, followed by an intravenous (IV) infusion to increase therapeutic Fxn levels in the cerebellar dentate nuclei and in the cardiomyocytes, respectively.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIDN Infusion targets the cerebellar dentate nuclei.\u003c\/li\u003e\n\u003cli\u003eIV Infusion targets the cardiomyocytes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; the dual-route administration for FA is a unique design feature not widely replicated by competitors in this space. SGT-212 is the \u003cstrong\u003eonly\u003c\/strong\u003e dual route gene therapy in development to treat Friedreich's ataxia with FDA IND clearance and Fast Track designation.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; requires specific surgical\/procedural expertise and construct design to execute both routes effectively, including the use of an FDA-approved, stereotactic, precision MRI-guided device for IDN infusion.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; the organization is actively advancing the program, with the Phase 1b FALCON clinical trial screening participants as of October 2025, with initiation expected in the fourth quarter of 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eOrganizational Milestone\u003c\/th\u003e\n\u003cth\u003eStatus\/Date\u003c\/th\u003e\n\u003cth\u003eAssociated Trial\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA IND Clearance\u003c\/td\u003e\n\u003ctd\u003eJanuary 7, 2025\u003c\/td\u003e\n\u003ctd\u003eFALCON (Phase 1b)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1b Trial Initiation Expected\u003c\/td\u003e\n\u003ctd\u003eQ4 2025\u003c\/td\u003e\n\u003ctd\u003eFALCON (Phase 1b)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eParticipant Screening Underway\u003c\/td\u003e\n\u003ctd\u003eOctober 2025\u003c\/td\u003e\n\u003ctd\u003eFALCON (Phase 1b)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Follow-up Period\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e5 years\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFALCON (Phase 1b)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained, as long as the dual-route proves superior in clinical outcomes over single-route approaches. Regulatory achievements provide an accelerated pathway.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA Fast Track designation granted in January 2025.\u003c\/li\u003e\n\u003cli\u003eFDA Rare Pediatric Disease designation granted in December 2025.\u003c\/li\u003e\n\u003cli\u003ePotential eligibility for priority review.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinancial Context (SLDB as of Q3 2025):\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Available-for-Sale Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$236.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnticipated Cash Runway\u003c\/td\u003e\n\u003ctd\u003eInto H1 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$38.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eSolid Biosciences Inc. (SLDB) - VRIO Analysis: 6. Regulatory Advantage (Orphan\/Fast Track\/RPD Designations)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Designations like Fast Track (SGT-501) and Rare Pediatric Disease (SGT-212, SGT-501) can accelerate FDA review and potentially provide a Priority Review Voucher (PRV) for SGT-212.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; these designations are common for rare disease drugs but are valuable nonetheless, especially the PRV potential.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; these are granted by the FDA based on the disease's profile, not the company's internal skill.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the regulatory team has successfully navigated early-stage filings, evidenced by IND clearance for SGT-212 on January 7, 2025 and IND clearance for SGT-501 on July 8, 2025. SGT-501 represents the third IND clearance in the past two years. Research and development expenses for SGT-212 in Q2 2025 were $1.0 million related to clinical and research costs, while SGT-501 costs decreased by $1.2 million in the same period. The company ended Q2 2025 with $268.1 million in cash, cash equivalents, and available-for-sale securities.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as designations are tied to the specific drug\/indication, not the company as a whole.\u003c\/p\u003e\n\u003cp\u003eThe specific regulatory milestones achieved for key pipeline assets are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset\u003c\/td\u003e\n\u003ctd\u003eIndication\u003c\/td\u003e\n\u003ctd\u003eOrphan Drug Designation (ODD)\u003c\/td\u003e\n\u003ctd\u003eFast Track (FT) Designation\u003c\/td\u003e\n\u003ctd\u003eRare Pediatric Disease (RPD) Designation\u003c\/td\u003e\n\u003ctd\u003eIND Clearance Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSGT-212\u003c\/td\u003e\n\u003ctd\u003eFriedreich's Ataxia (FA)\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated as granted in latest search, but RPD implies rare disease focus\u003c\/td\u003e\n\u003ctd\u003eGranted (Earlier in 2025)\u003c\/td\u003e\n\u003ctd\u003eGranted (December 1, 2025)\u003c\/td\u003e\n\u003ctd\u003eJanuary 7, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSGT-501\u003c\/td\u003e\n\u003ctd\u003eCPVT\u003c\/td\u003e\n\u003ctd\u003eGranted\u003c\/td\u003e\n\u003ctd\u003eGranted (July 23, 2025)\u003c\/td\u003e\n\u003ctd\u003eGranted\u003c\/td\u003e\n\u003ctd\u003eJuly 8, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe RPD designation for SGT-212 carries the potential to receive a pediatric priority review voucher (PRV).\u003c\/p\u003e\n\u003cp\u003eThe company's clinical trial initiation timelines are tied to these regulatory achievements:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSGT-212 Phase 1b trial initiation expected in Q4 2025.\u003c\/li\u003e\n\u003cli\u003eSGT-501 Phase 1b trial initiation expected in Q4 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSolid Biosciences Inc. (SLDB) - VRIO Analysis: 7. Clinical Trial Infrastructure and Recruitment Momentum\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Operational strength demonstrated by the ongoing global Phase 1\/2 INSPIRE DUCHENNE trial, with participant dosing ongoing across multiple international locations.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eParticipants Dosed (as of October 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Clinical Trial Sites (as of October 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographic Locations\u003c\/td\u003e\n\u003ctd\u003eUnited States, Canada, Italy and the United Kingdom\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Total Dosed Participants\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e30\u003c\/strong\u003e (by early 2026)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDay 90 Microdystrophin Expression (Mean Western Blot)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e58%\u003c\/strong\u003e (from 10 treated participants)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDay 90 Beta-Sarcoglycan Positive Fibers (Mean IF)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e50%\u003c\/strong\u003e (from 10 treated participants)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorrelation Coefficient (Microdystrophin vs. Beta-Sarcoglycan)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003er = 0.95\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorrelation Coefficient (Microdystrophin vs. CK Levels)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003er = -0.78\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAAV-SLB101 Capsid Agreements Executed\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e30\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; establishing and managing a multi-national clinical site network spanning the US, Canada, Italy, and the UK, while achieving 23 doses as of October 31, 2025, requires specialized regulatory and logistical expertise.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; the established relationships with the 15 active sites and patient trust are harder to copy quickly, though competitors can build site networks.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the momentum, evidenced by dosing 23 participants and expecting to reach 30 by early 2026, is a direct result of effective clinical operations, including the activation of sites to support expanded enrollment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as site relationships can shift, but the current operational tempo and positive data points (e.g., 58% mean microdystrophin expression) are a current strength.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe trial is designed to enroll participants across the United States, Canada, the United Kingdom, and Italy.\u003c\/li\u003e\n\u003cli\u003eThe company expects to initiate a separate randomized, double-blind, placebo-controlled trial outside the United States in the \u003cstrong\u003efourth quarter of 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe proprietary AAV-SLB101 capsid has secured over \u003cstrong\u003e30\u003c\/strong\u003e agreements with corporations, institutions, and academic labs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSolid Biosciences Inc. (SLDB) - VRIO Analysis: 8. Next-Generation Capsid Library Development\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Platform for future pipeline expansion; final capsid selection for the first cardiac library anticipated in the \u003cstrong\u003efourth quarter of 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Building multiple cardiac and neuromuscular capsid and promoter libraries.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Core R\u0026amp;D capability; AAV-SLB101 generally well tolerated in \u003cstrong\u003e23\u003c\/strong\u003e pediatric participants dosed in the INSPIRE DUCHENNE trial as of October 31, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Structured R\u0026amp;D process; Research and Development expenses for the second quarter of 2025 were \u003cstrong\u003e$32.4 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained by licensing revenue potential; Solid has executed more than \u003cstrong\u003e30\u003c\/strong\u003e agreements and licenses for AAV-SLB101.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eContext\/Program\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Selection Timeline\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ4 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFirst cardiac capsid library\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull Capsid Ratio (Research Scale)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e80%\u003c\/strong\u003e, \u003cstrong\u003e85%\u003c\/strong\u003e, \u003cstrong\u003e92%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSGT-003, SGT-501, SGT-601 respectively\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAAV-SLB101 Dosing Experience\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e23\u003c\/strong\u003e participants\u003c\/td\u003e\n\u003ctd\u003eINSPIRE DUCHENNE trial as of October 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAAV-SLB101 Licensing Agreements\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e30\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eExecuted agreements\/licenses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2025 R\u0026amp;D Expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$32.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eResearch and Development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (End Q2 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$268.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCash, cash equivalents and available-for-sale securities\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eBuilding multiple cardiac and neuromuscular capsid and promoter libraries.\u003c\/li\u003e\n\u003cli\u003eExclusive license to develop and commercialize \u003cstrong\u003esix\u003c\/strong\u003e undisclosed cardiac gene therapy programs.\u003c\/li\u003e\n\u003cli\u003eFull-to-empty capsid ratios at research scales: \u003cstrong\u003e80%\u003c\/strong\u003e for SGT-003, \u003cstrong\u003e85%\u003c\/strong\u003e for SGT-501, and \u003cstrong\u003e92%\u003c\/strong\u003e for SGT-601.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSolid Biosciences Inc. (SLDB) - VRIO Analysis: 9. Commitment to R\u0026amp;D Investment\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The high R\u0026amp;D spend, reaching \u003cstrong\u003e$38.9 million\u003c\/strong\u003e in Q3 2025, signals a clear commitment to advancing the pipeline and technology, which reassures investors and potential partners.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; most clinical-stage biotechs spend heavily on R\u0026amp;D, but the level relative to cash position is key. The R\u0026amp;D spend for the first nine months of 2025 reached \u003cstrong\u003e$102.2 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; it's a financial choice, though the quality of the spend is what matters.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the spending is clearly directed at clinical execution and platform advancement.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as R\u0026amp;D spend can be cut if financing dries up. The cash position as of September 30, 2025, was \u003cstrong\u003e$236.1 million\u003c\/strong\u003e, with an expected operational runway into the first half of 2027.\u003c\/p\u003e\n\n\u003cp\u003eThe commitment is quantified by the sequential increase in quarterly R\u0026amp;D investment:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeriod\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D Expense\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$38.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$32.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNine Months Ended Sept 30, 2025 (YTD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$102.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe organization directs this investment across its core pipeline assets, as evidenced by year-to-date spending:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eSGT-003 Development: \u003cstrong\u003e$39.7 million\u003c\/strong\u003e in R\u0026amp;D expenses YTD 2025.\u003c\/li\u003e\n\u003cli\u003eSGT-501: \u003cstrong\u003e$8.2 million\u003c\/strong\u003e YTD 2025.\u003c\/li\u003e\n\u003cli\u003eSGT-601: \u003cstrong\u003e$6.5 million\u003c\/strong\u003e YTD 2025.\u003c\/li\u003e\n\u003cli\u003eSGT-212: \u003cstrong\u003e$3.8 million\u003c\/strong\u003e YTD 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe Q3 2025 GAAP net loss was \u003cstrong\u003e$(0.48)\u003c\/strong\u003e per share.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516251889813,"sku":"sldb-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/sldb-vrio-analysis.png?v=1740216444","url":"https:\/\/dcf-model.com\/products\/sldb-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}